Medindia LOGIN REGISTER
Medindia
Advertisement

Repurposing of Existing Drugs Finds Compounds Active Against MERS Coronavirus

by Bidita Debnath on May 26, 2014 at 11:45 PM
 Repurposing of Existing Drugs Finds Compounds Active Against MERS Coronavirus

WHAT: Clinicians treating people suffering from Middle East respiratory syndrome (MERS) currently have no drugs specifically targeted to the MERS coronavirus (MERS-CoV).

It is a virus first detected in humans in 2012 that has since caused 614 laboratory-confirmed infections, including 181 that were fatal, according to the World Health Organization. The case count escalated sharply in the spring of this year, and the first cases in the United States were announced in early May. To address the urgent need for therapies, researchers supported by the National Institutes of Health screened a set of 290 compounds already approved by the U.S. Food and Drug Administration or far advanced in clinical development for other indications to determine if any might also show potential for working against MERS-CoV.

Advertisement

From the group of 290 compounds, the scientists identified 27 that, in test tube experiments, showed activity against both MERS-CoV and the related SARS coronavirus. These included compounds that inhibited the viruses' ability to enter and infect cells. The active compounds belong to 13 different classes of pharmaceuticals, including drugs normally used to treat cancer and psychiatric conditions, and provide leads for continued study in animals and potentially for study in people. The research team is now studying the effects of some of the identified compounds in mice experimentally infected with MERS-CoV.

"Given development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses," the investigators noted in the paper now online in the journal Antimicrobial Agents and Chemotherapy. The research was a collaboration between investigators at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, and Matthew B. Frieman, Ph.D., of the University of Maryland School of Medicine in Baltimore.

Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Coronavirus News

High Steroid Dose for COVID-19: Less Effective in India Than Europe?
A larger dose of dexamethasone (12 mg) appeared to be less effective than the standard dose (6 mg) for COVID-19 patients in India.
Surge in Premature Births Linked to COVID, Vaccination Proves Protective
New study explores how COVID-19 vaccination might have spared a generation of American children from the enduring health challenges and expenses linked to premature birth.
Lower COVID-19 Booster Dose for Adults Optimizes Immunity
Recent study reveals the immune response in adults after reducing the standard COVID-19 booster vaccine.
COVID-19: India Reports 31 New Infections
India's COVID case count reached 450.01 million (4.50 crore), with the administration of 2.21 billion (220.67 crore) COVID vaccine doses.
Is the Uptake of COVID-19 Vaccines Lower Than Anticipated?
COVID-19 is a significant cause of hospitalization and mortality, especially among older adults and those with specific underlying health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Repurposing of Existing Drugs Finds Compounds Active Against MERS Coronavirus Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests